To reflect the variety of DDR defects observed in NB tumours, we chose a panel of NB cell line of varying MYCN, 11q and TP53 status to interrogate what features would lead to sensitivity to ATR and PARP inhibitors. This evidence concerns the gene ATR and neoplasm.